glenmark pharmaceuticals
Jump to
184 Results Found
  • Glenmark gains 3% on licensing agreement with Torrent Pharma for anti-diabetes drug Jul 11, 2019 10:42 AM IST

    Glenmark gains 3% on licensing agreement with Torrent Pharma for anti-diabetes drug

    Glenmark will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark 'Zucator' in India.

  • Glenmark gets final nod from USFDA for angina treatment drug Jul 09, 2019 02:18 PM IST

    Glenmark gets final nod from USFDA for angina treatment drug

    Ranolazine is used to treat chronic angina.

  • Glenmark Pharma gains 4% on USFDA approval for anti-anginal drug Jul 09, 2019 12:07 PM IST

    Glenmark Pharma gains 4% on USFDA approval for anti-anginal drug

    Glenmark's current portfolio consists of 158 products authorised for distribution in the US marketplace and 57 ANDA’s pending approval with the USFDA

  • Glenmark Pharmaceuticals says USFDA has issued CRL for Ryaltris Jun 22, 2019 03:27 PM IST

    Glenmark Pharmaceuticals says USFDA has issued CRL for Ryaltris

    The company said it will continue to pursue regulatory approval for Ryaltris and work closely with the FDA to determine the appropriate next steps.

  • Hold Glenmark Pharmaceuticals; target of Rs 565: ICICI Direct Jun 18, 2019 12:03 PM IST

    Hold Glenmark Pharmaceuticals; target of Rs 565: ICICI Direct

    ICICI Direct recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 565 in its research report dated May 30, 2019.

  • Hold Glenmark Pharmaceuticals; target of Rs 595: Sharekhan Jun 03, 2019 04:43 PM IST

    Hold Glenmark Pharmaceuticals; target of Rs 595: Sharekhan

    Sharekhan recommended Hold rating on Glenmark Pharmaceuticals with a target price of Rs 595 in its research report dated May 30, 2019.

  • Glenmark Q4 net profit up 6.62% at Rs 161.66 cr May 29, 2019 10:45 PM IST

    Glenmark Q4 net profit up 6.62% at Rs 161.66 cr

    The company's consolidated revenue for 2018-19 stood at Rs 9,865.46 crore, compared to Rs 9,103.07 crore in the preceding fiscal.

  • Glenmark Pharmaceuticals gets USFDA nod for acid reflux medication May 14, 2019 10:50 AM IST

    Glenmark Pharmaceuticals gets USFDA nod for acid reflux medication

    The approved products is a generic version of AstraZeneca Pharmaceuticals' Nexium delayed-release capsules.

  • Glenmark Pharmaceuticals appoints Yasir Rawjee as CEO of Glenmark Life Sciences May 07, 2019 11:12 AM IST

    Glenmark Pharmaceuticals appoints Yasir Rawjee as CEO of Glenmark Life Sciences

    Rawjee joins Glenmark Life Sciences from Mylan, where most recently he was the Head of Global API Operations.

  • Glenmark Pharmaceuticals Q4 PAT seen up 30% YoY to Rs. 196.4 cr: Prabhudas Lilladher Apr 12, 2019 01:11 PM IST

    Glenmark Pharmaceuticals Q4 PAT seen up 30% YoY to Rs. 196.4 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 10.8 percent Y-o-Y (down 0.8 percent Q-o-Q) to Rs. 2,490.2 crore, according to Prabhudas Lilladher.

  • Glenmark Pharmaceuticals gets USFDA nod for generic version of acne treatment gel Mar 15, 2019 03:52 PM IST

    Glenmark Pharmaceuticals gets USFDA nod for generic version of acne treatment gel

    Glenmark's current portfolio consists of 151 products authorised for distribution in the US.

  • Glenmark Pharma appoints Alessandro Riva as CEO of its new innovation company in US Mar 06, 2019 10:37 AM IST

    Glenmark Pharma appoints Alessandro Riva as CEO of its new innovation company in US

    "Alessandro is currently Executive Vice President, Oncology Therapeutics and Cell Therapy for Gilead Sciences. The appointment is effective April 2, 2019," Glenmark Pharma said in a regulatory filing.

  • Glenmark Pharma gets USFDA nod for hypertension drug Mar 05, 2019 10:59 AM IST

    Glenmark Pharma gets USFDA nod for hypertension drug

    The approved products is a generic version of Boehringer Ingelheim Pharmaceuticals Inc's Micardis HCT tablets.

  • Glenmark gets USFDA nod for generic skin inflammation treatment foam Feb 18, 2019 12:59 PM IST

    Glenmark gets USFDA nod for generic skin inflammation treatment foam

    The approval has been granted by the USFDA to Glenmark Pharmaceuticals, US, for clobetasol propionate foam, 0.05 percent, a generic version of Olux Foam, 0.05 percent, of Mylan Pharmaceuticals, the company said in a statement.

  • Glenmark Pharma gets USFDA nod for drug for patients on dialysis Feb 11, 2019 12:32 PM IST

    Glenmark Pharma gets USFDA nod for drug for patients on dialysis

    "Glenmark Pharmaceuticals Inc, USA (Glenmark) has been granted final approval by the United States Food and Drug Administration (USFDA) for Sevelamer Hydrochloride tablets in the strengths of 400 mg and 800 mg," the company said in a BSE filing.

  • Glenmark inks pact with South Korea's Yuhan Corp to commercialise Ryaltris Jan 10, 2019 02:12 PM IST

    Glenmark inks pact with South Korea's Yuhan Corp to commercialise Ryaltris

    Ryaltris is indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age

  • Glenmark Pharma eyes up to 15% consolidated revenue growth over 3 to 5 years Jan 08, 2019 04:52 PM IST

    Glenmark Pharma eyes up to 15% consolidated revenue growth over 3 to 5 years

    Glenmark is targeting a consolidated revenue growth of 12-15 percent over the next 3-5 years, while focusing on margin expansion, the company said.

  • Glenmark gets USFDA approval for ear drops Dec 18, 2018 11:08 AM IST

    Glenmark gets USFDA approval for ear drops

    Glenmark Pharmaceuticals Inc, USA has been granted final approval by the USFDA for Fluocinolone Acetonide Oil, 0.01 per cent (ear drops), a generic version of DermOtic Oil.

  • Glenmark gets USFDA nod for skin ointment Dec 17, 2018 11:38 AM IST

    Glenmark gets USFDA nod for skin ointment

    Glenmark said it is eligible for 180 days of competitive generic therapy (CGT) exclusivity upon commercialisation.

  • Glenmark Pharma gets tentative USFDA nod for skin treatment drug Nov 26, 2018 10:58 AM IST

    Glenmark Pharma gets tentative USFDA nod for skin treatment drug

    The approved product is a generic version of Mylan Pharmaceuticals Inc's Olux-E Foam, 0.05 per cent.

  • Glenmark gets USFDA nod for pneumonia treatment drug Nov 22, 2018 11:06 AM IST

    Glenmark gets USFDA nod for pneumonia treatment drug

    The approved drug is a generic version of GlaxoSmithKline's Mepron Oral Suspension of similar strength.

  • Glenmark Pharma gains 2% on USFDA approval for antimicrobial drug Nov 22, 2018 10:04 AM IST

    Glenmark Pharma gains 2% on USFDA approval for antimicrobial drug

    Atovaquone is a generic version of Mepron oral suspension, 750 mg/5 mL, of GlaxoSmithKline LLC.

  • Glenmark gets USFDA nod for generic acne treatment gel Nov 20, 2018 01:12 PM IST

    Glenmark gets USFDA nod for generic acne treatment gel

    The approval granted to Glenmark Pharmaceuticals Inc by by the US Food and Drug Administration (USFDA) is for Azelaic Acid Gel, 15 per cent, which is a generic version of Finacea Gel (15 per cent) of Leo Pharma, the company said in a statement.

  • Glenmark gets USFDA nod for multiple sclerosis medication Nov 16, 2018 10:50 AM IST

    Glenmark gets USFDA nod for multiple sclerosis medication

    Glenmark Pharmaceuticals, USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Teriflunomide tablets in the strengths of 7 mg and 14 mg, the company said in a BSE filing.

  • Glenmark to launch phase 1 trial in solid tumors for anti-myeloma drug Nov 08, 2018 11:41 AM IST

    Glenmark to launch phase 1 trial in solid tumors for anti-myeloma drug

    "The company intends to file an Investigational New Drug (IND) application for GBR 1342 in solid tumors and initiate a clinical trial in 2019," the company said in a regulatory filing.

Sections